(CRH) CRH - Overview
Exchange: NYSE •
Country: Ireland •
Currency: USD •
Type: Common Stock •
ISIN: IE0001827041
Stock: Aggregates, Cement, Ready-Mixed Concrete, Asphalt, Precast Concrete
Total Rating 55
Risk 95
Buy Signal 0.74
Dividends
| Dividend Yield | 1.44% |
| Yield on Cost 5y | 3.94% |
| Yield CAGR 5y | 6.28% |
| Payout Consistency | 90.0% |
| Payout Ratio | 28.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 31.1% |
| Relative Tail Risk | -3.54% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.74 |
| Alpha | 8.58 |
| Character TTM | |
|---|---|
| Beta | 1.220 |
| Beta Downside | 1.158 |
| Drawdowns 3y | |
|---|---|
| Max DD | 27.01% |
| CAGR/Max DD | 1.49 |
Description: CRH CRH January 28, 2026
CRH plc (NYSE:CRH) is a Dublin-based, globally diversified building-materials group operating through three segments-Americas Materials Solutions, Americas Building Solutions, and International Solutions. It supplies aggregates, cement, ready-mix concrete, asphalt, precast concrete, polymer-based products, and a broad suite of engineered construction and infrastructure solutions across North America, Europe and other markets, serving public infrastructure, residential/commercial construction, and utility-critical projects.
Key recent metrics (FY 2023/24): revenue €30.5 bn, adjusted EBITDA €4.8 bn (EBITDA margin ≈ 15.7%), free cash flow €1.2 bn, net-debt/EBITDA ≈ 1.2×, and a dividend yield around 3.5%. The business is benefitting from a 4 % YoY rise in U.S. construction spending, the EU’s €1.5 tn post-pandemic infrastructure plan, and sustained demand for resilient utility-grade concrete amid higher energy-transition spending; however, higher interest rates and raw-material price volatility remain downside risks.
For a deeper quantitative view, check ValueRay’s CRH analysis dashboard.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 3.21b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.37 > 1.0 |
| NWC/Revenue: 12.97% < 20% (prev 11.75%; Δ 1.22% < -1%) |
| CFO/TA 0.11 > 3% & CFO 5.28b > Net Income 3.21b |
| Net Debt (14.05b) to EBITDA (7.04b): 2.00 < 3 |
| Current Ratio: 1.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (675.5m) vs 12m ago -1.46% < -2% |
| Gross Margin: 36.12% > 18% (prev 0.35%; Δ 3577 % > 0.5%) |
| Asset Turnover: 71.55% > 50% (prev 69.32%; Δ 2.23% > 0%) |
| Interest Coverage Ratio: 7.04 > 6 (EBITDA TTM 7.04b / Interest Expense TTM 701.5m) |
Altman Z'' 3.44
| A: 0.09 (Total Current Assets 14.39b - Total Current Liabilities 9.90b) / Total Assets 49.97b |
| B: 0.43 (Retained Earnings 21.40b / Total Assets 49.97b) |
| C: 0.10 (EBIT TTM 4.94b / Avg Total Assets 48.34b) |
| D: 0.73 (Book Value of Equity 21.27b / Total Liabilities 28.94b) |
| Altman-Z'' Score: 3.44 = A |
Beneish M -3.05
| DSRI: 0.95 (Receivables 5.94b/5.86b, Revenue 34.59b/32.38b) |
| GMI: 0.98 (GM 36.12% / 35.27%) |
| AQI: 1.05 (AQ_t 0.28 / AQ_t-1 0.27) |
| SGI: 1.07 (Revenue 34.59b / 32.38b) |
| TATA: -0.04 (NI 3.21b - CFO 5.28b) / TA 49.97b) |
| Beneish M-Score: -3.05 (Cap -4..+1) = AA |
What is the price of CRH shares?
As of January 30, 2026, the stock is trading at USD 123.68 with a total of 5,504,675 shares traded.
Over the past week, the price has changed by -0.65%, over one month by -2.88%, over three months by +4.75% and over the past year by +26.65%.
Over the past week, the price has changed by -0.65%, over one month by -2.88%, over three months by +4.75% and over the past year by +26.65%.
Is CRH a buy, sell or hold?
CRH has received a consensus analysts rating of 4.43.
Therefore, it is recommended to buy CRH.
- StrongBuy: 14
- Buy: 5
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CRH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 140 | 13.2% |
| Analysts Target Price | 140 | 13.2% |
| ValueRay Target Price | 165 | 33.4% |
CRH Fundamental Data Overview January 27, 2026
P/E Trailing = 24.519
P/E Forward = 20.284
P/S = 2.2254
P/B = 3.5232
P/EG = 2.1499
Revenue TTM = 34.59b USD
EBIT TTM = 4.94b USD
EBITDA TTM = 7.04b USD
Long Term Debt = 14.73b USD (from longTermDebt, last quarter)
Short Term Debt = 3.69b USD (from shortTermDebt, last quarter)
Debt = 17.63b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.05b USD (from netDebt column, last quarter)
Enterprise Value = 95.55b USD (82.12b + Debt 17.63b - CCE 4.20b)
Interest Coverage Ratio = 7.04 (Ebit TTM 4.94b / Interest Expense TTM 701.5m)
EV/FCF = 37.83x (Enterprise Value 95.55b / FCF TTM 2.53b)
FCF Yield = 2.64% (FCF TTM 2.53b / Enterprise Value 95.55b)
FCF Margin = 7.30% (FCF TTM 2.53b / Revenue TTM 34.59b)
Net Margin = 9.27% (Net Income TTM 3.21b / Revenue TTM 34.59b)
Gross Margin = 36.12% ((Revenue TTM 34.59b - Cost of Revenue TTM 22.09b) / Revenue TTM)
Gross Margin QoQ = 38.93% (prev 39.45%)
Tobins Q-Ratio = 1.91 (Enterprise Value 95.55b / Total Assets 49.97b)
Interest Expense / Debt = 1.19% (Interest Expense 209.0m / Debt 17.63b)
Taxrate = 22.28% (428.0m / 1.92b)
NOPAT = 3.84b (EBIT 4.94b * (1 - 22.28%))
Current Ratio = 1.45 (Total Current Assets 14.39b / Total Current Liabilities 9.90b)
Debt / Equity = 0.89 (Debt 17.63b / totalStockholderEquity, last quarter 19.90b)
Debt / EBITDA = 2.00 (Net Debt 14.05b / EBITDA 7.04b)
Debt / FCF = 5.56 (Net Debt 14.05b / FCF TTM 2.53b)
Total Stockholder Equity = 19.74b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.63% (Net Income 3.21b / Total Assets 49.97b)
RoE = 16.24% (Net Income TTM 3.21b / Total Stockholder Equity 19.74b)
RoCE = 14.33% (EBIT 4.94b / Capital Employed (Equity 19.74b + L.T.Debt 14.73b))
RoIC = 10.07% (NOPAT 3.84b / Invested Capital 38.13b)
WACC = 8.73% (E(82.12b)/V(99.75b) * Re(10.41%) + D(17.63b)/V(99.75b) * Rd(1.19%) * (1-Tc(0.22)))
Discount Rate = 10.41% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.14%
[DCF Debug] Terminal Value 72.22% ; FCFF base≈2.39b ; Y1≈1.99b ; Y5≈1.47b
Fair Price DCF = 14.24 (EV 23.57b - Net Debt 14.05b = Equity 9.52b / Shares 668.5m; r=8.73% [WACC]; 5y FCF grow -20.07% → 2.90% )
EPS Correlation: 11.02 | EPS CAGR: 0.0% | SUE: -4.0 | # QB: 0
Revenue Correlation: -44.67 | Revenue CAGR: -8.21% | SUE: -0.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.20 | Chg30d=-0.015 | Revisions Net=-2 | Analysts=6
EPS next Year (2026-12-31): EPS=6.07 | Chg30d=+0.004 | Revisions Net=+0 | Growth EPS=+8.8% | Growth Revenue=+6.2%
P/E Forward = 20.284
P/S = 2.2254
P/B = 3.5232
P/EG = 2.1499
Revenue TTM = 34.59b USD
EBIT TTM = 4.94b USD
EBITDA TTM = 7.04b USD
Long Term Debt = 14.73b USD (from longTermDebt, last quarter)
Short Term Debt = 3.69b USD (from shortTermDebt, last quarter)
Debt = 17.63b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.05b USD (from netDebt column, last quarter)
Enterprise Value = 95.55b USD (82.12b + Debt 17.63b - CCE 4.20b)
Interest Coverage Ratio = 7.04 (Ebit TTM 4.94b / Interest Expense TTM 701.5m)
EV/FCF = 37.83x (Enterprise Value 95.55b / FCF TTM 2.53b)
FCF Yield = 2.64% (FCF TTM 2.53b / Enterprise Value 95.55b)
FCF Margin = 7.30% (FCF TTM 2.53b / Revenue TTM 34.59b)
Net Margin = 9.27% (Net Income TTM 3.21b / Revenue TTM 34.59b)
Gross Margin = 36.12% ((Revenue TTM 34.59b - Cost of Revenue TTM 22.09b) / Revenue TTM)
Gross Margin QoQ = 38.93% (prev 39.45%)
Tobins Q-Ratio = 1.91 (Enterprise Value 95.55b / Total Assets 49.97b)
Interest Expense / Debt = 1.19% (Interest Expense 209.0m / Debt 17.63b)
Taxrate = 22.28% (428.0m / 1.92b)
NOPAT = 3.84b (EBIT 4.94b * (1 - 22.28%))
Current Ratio = 1.45 (Total Current Assets 14.39b / Total Current Liabilities 9.90b)
Debt / Equity = 0.89 (Debt 17.63b / totalStockholderEquity, last quarter 19.90b)
Debt / EBITDA = 2.00 (Net Debt 14.05b / EBITDA 7.04b)
Debt / FCF = 5.56 (Net Debt 14.05b / FCF TTM 2.53b)
Total Stockholder Equity = 19.74b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.63% (Net Income 3.21b / Total Assets 49.97b)
RoE = 16.24% (Net Income TTM 3.21b / Total Stockholder Equity 19.74b)
RoCE = 14.33% (EBIT 4.94b / Capital Employed (Equity 19.74b + L.T.Debt 14.73b))
RoIC = 10.07% (NOPAT 3.84b / Invested Capital 38.13b)
WACC = 8.73% (E(82.12b)/V(99.75b) * Re(10.41%) + D(17.63b)/V(99.75b) * Rd(1.19%) * (1-Tc(0.22)))
Discount Rate = 10.41% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.14%
[DCF Debug] Terminal Value 72.22% ; FCFF base≈2.39b ; Y1≈1.99b ; Y5≈1.47b
Fair Price DCF = 14.24 (EV 23.57b - Net Debt 14.05b = Equity 9.52b / Shares 668.5m; r=8.73% [WACC]; 5y FCF grow -20.07% → 2.90% )
EPS Correlation: 11.02 | EPS CAGR: 0.0% | SUE: -4.0 | # QB: 0
Revenue Correlation: -44.67 | Revenue CAGR: -8.21% | SUE: -0.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.20 | Chg30d=-0.015 | Revisions Net=-2 | Analysts=6
EPS next Year (2026-12-31): EPS=6.07 | Chg30d=+0.004 | Revisions Net=+0 | Growth EPS=+8.8% | Growth Revenue=+6.2%